PeptideStack
5.2kquestions
20kanswers
220users

Would you re-test tirzepatide after ten weeks at 4 °C, or accept the original certificate?

Asked 17 Jul 2026Modified 1 min agoViewed 6.2k times
18

The specifics, since they change the answer: tirzepatide · ten weeks · 4 °C.

I would like to define my thresholds before I have a result, for obvious reasons.

I want a plan with explicit stopping rules, not just steps.

How do I make this decision on evidence rather than on feel?

batch-testing
batch-testing

Testing at the batch or lot level: sampling plans, how many vials from a lot need testing to say anything about the lot, and the difference…

865 questions
peptide-stability
peptide-stability

The chemistry of peptide degradation: deamidation, oxidation, hydrolysis, aggregation and fibrillation, and how temperature, pH, ionic strength,…

832 questions
coa
coa

Certificates of analysis: what fields a useful one carries, how to tell a real analytical report from a marketing document, batch and lot…

749 questions
shareeditfollowflag
GA
askedgrainne_ahearn13k1617 Jul 2026
Is there a reason to prefer the second method over the first, other than cost? – plate_count_9k 6 months ago
add a comment

5 Answers

Accepted answer first, then by votes
46

Accepted answer

Put another way, thermal history during shipping is different for every vial, so a lot that experienced thermal abuse may have internal variation even if it was originally homogeneous.

If you have reason to suspect inhomogeneity — different appearance in different vials, or a long or warm shipment — testing more vials is the diagnostic move.

What each test answers

TestAnswersDoes NOT answer
RP-HPLC, area %What fraction of detected material is the targetHow much target is present
Quantified contentMilligrams of peptide per vialWhat the impurities are
ESI-MS identityWhether the molecular weight matchesPurity, or isomeric substitution
Peptide mappingSequence, localised to a fragmentQuantity
Karl FischerWater content of the solidSolvent content
LAL endotoxinPyrogen load in EU/mgSterility
Sterility testGrowth in defined media over 14 daysEndotoxin, or bioburden count

If the entire lot failed qualification, a retest on a different vial is sometimes done, but reporting a retest result under the same lot number is misleading.

Lyophilised peptide homogeneity studies show that vial-to-vial variation is usually small but occasionally large, depending on the distribution in the freeze-dryer.

Assume segregation is possible, and design your sampling to catch it if it exists.

shareimprove this answerflag
LS
answered · acceptedlow_dead_space42k3823 Jul 2026
Sponsored

Sigma-Aldrich - Certified Reference Materials

Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.

Shop standards
39

The relevant detail is that start from the question: how many vials from this lot do I need to test to claim that the lot meets specification, and the answer depends on both the lot size and the acceptable risk.

Stratified sampling — testing one vial from the top, one from the middle, and one from the bottom of a shipment — is cheap insurance against segregation.

The sample size determination requires choosing a confidence level and an acceptable error rate, and the smaller the error rate you want, the larger your sample must be.

Published data on lot homogeneity from manufacturers who sample multiple vials consistently find variation below the published specifications, suggesting the sampling plans work.

If testing multiple vials, state how many you tested and why you chose those vials.

edited 23 Aug 2026 by Dr_Nadia_Farsi — corrected a unit error in the worked example

shareimprove this answerflag
DF
answeredDr_Nadia_Farsi90k25826 Jul 2026
19

Mechanically, two vials tested from a lot of ten is very different from two vials tested from a lot of ten thousand, and most certificates do not state the lot size.

For a quantitative result like content, the acceptable range determines how many vials you need to test to establish the lot complies.

More usefully, under AQL sampling plans, testing two vials from a fifty-vial lot gives you an operating characteristic curve that tells you what risks you are accepting.

The practical summary: a lot number without a sampling statement is a lot number without meaning.

shareimprove this answerflag
DV
answereddead_volume49k3820 Jul 2026
Any reason this would differ for a longer peptide? – kwn_analytical 8 months ago
add a comment
16

The failure mode here is publishing a result that applies to the tested vial alone while implying it applies to the entire lot.

Published segregation failures show that even modern automated processes sometimes produce lots with measurable vial-to-vial variation.

Assume segregation is possible, and design your sampling to catch it if it exists.

shareimprove this answerflag
SS
answeredswirl_dont_shake19k2830 Jul 2026
For what it is worth, my own result was within half a per cent of this. – a_lindgren 4 months ago
Any reason this would differ for a longer peptide? – Dr_Priya_Raghunathan 6 months ago
add a comment
12

Mechanically, sampling plans exist precisely because testing everything is expensive, and they define the statistical relationship between sample size and lot-wide inference.

Testing a vial that has been open in the lab for three months is testing aged material, not the fresh lot, and the result should be explicitly noted as a retest.

I would treat a "complies with" statement without sampling details as a claim rather than as evidence.

If testing multiple vials, state how many you tested and why you chose those vials.

shareimprove this answerflag
HV
answeredh_villanueva50k3826 Jul 2026
5Good answer, but the confidence interval in the cited trial is wider than implied. – Dr_Elias_Weiss 5 months ago
add a comment

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.